Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday after it announced disappointing results of a new drug study.

Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Patients receiving Mounjaro, also called Zepbound in the US, lost an average of 22.5 per cent of their weight in phase three ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...